We are live on ! Find out more
XENE icon

Xenon Pharmaceuticals
XENE

70 hedge funds and large institutions have $314M invested in Xenon Pharmaceuticals in 2020 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 22 increasing their positions, 18 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more funds holding in top 10

Funds holding in top 10: 2 → 3 (+1)

38% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 13

28% more capital invested

Capital invested by funds: $245M → $314M (+$68.7M)

22% more repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 18

6.96% more ownership

Funds ownership: 72.3% → 79.26% (+7%)

6% more funds holding

Funds holding: 66 → 70 (+4)

Holders
70
Holders Change
+4
Holders Change %
+6.06%
% of All Funds
1.54%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.07%
New
18
Increased
22
Reduced
18
Closed
13
Calls
$6K
Puts
–
Net Calls
+$6K
Net Calls Change
-$247K

Top Buyers

Rank Fund Capital Flow
1
CCM
Consonance Capital Management
New York
+$28.2M
2
Fidelity Investments
Fidelity Investments
Massachusetts
+$22.6M
3
O
OrbiMed
New York
+$14.6M
4
BI
BVF Inc
California
+$10.3M
5
BC
Boxer Capital
California
+$8.54M

Top Sellers

Rank Fund Capital Flow
1
ACP
Acuta Capital Partners
California
-$4.12M
2
Point72 Asset Management
Point72 Asset Management
Connecticut
-$3.86M
3
SCM
Soleus Capital Management
Connecticut
-$2.11M
4
EP
Eversept Partners
New York
-$2.05M
5
GPCM
Granite Point Capital Management
Massachusetts
-$1.86M
Name Holding Trade Value Shares
Change 		Change in
Stake
BCM
26
Burrage Capital Management
Massachusetts
$2.11M +$2.85M +200,000 New
DMK
27
David M. Knott
$1.99M -$291K -20,453 -10%
AGA
28
Altrinsic Global Advisors
Connecticut
$1.93M -$142K -10,000 -6%
AS
29
Altshuler Shaham
Israel
$1.72M +$413 +29 +0%
D.E. Shaw & Co
30
D.E. Shaw & Co
New York
$1.62M +$1.36M +95,631 +204%
GPCM
31
Granite Point Capital Management
Massachusetts
$1.61M -$1.86M -130,883 -48%
GIM
32
Granahan Investment Management
Massachusetts
$1.26M +$59.2K +4,160 +4%
GCA
33
Genesee Capital Advisors
New York
$1.21M +$1.52M +106,587 New
Deutsche Bank
34
Deutsche Bank
Germany
$1.08M +$1.31M +91,946 +2,934%
Two Sigma Investments
35
Two Sigma Investments
New York
$1M +$168K +11,788 +15%
EP
36
Eversept Partners
New York
$812K -$2.05M -144,018 -67%
BFM
37
Boothbay Fund Management
New York
$737K +$199K +13,982 +27%
Two Sigma Advisers
38
Two Sigma Advisers
New York
$720K +$433K +30,400 +92%
Northern Trust
39
Northern Trust
Illinois
$664K +$206K +14,456 +33%
JP Morgan Chase
40
JP Morgan Chase
New York
$568K -$121K -8,474 -14%
California Public Employees Retirement System
41
California Public Employees Retirement System
California
$565K -$124K -8,700 -15%
PNC Financial Services Group
42
PNC Financial Services Group
Pennsylvania
$518K – – –
SC
43
Scotia Capital
Ontario, Canada
$471K -$299K -20,963 -34%
Royal Bank of Canada
44
Royal Bank of Canada
Ontario, Canada
$465K -$79.2K -5,558 -12%
TI
45
Trexquant Investment
Connecticut
$361K +$453K +31,793 New
NSEDCP
46
NJ State Employees Deferred Compensation Plan
New Jersey
$284K – – –
MWNA
47
Marshall Wace North America
New York
$282K +$141K +9,873 +66%
PP
48
PDT Partners
New York
$250K +$315K +22,089 New
Squarepoint
49
Squarepoint
New York
$227K -$171K -12,037 -38%
Geode Capital Management
50
Geode Capital Management
Massachusetts
$218K – – –
1
2
3 4

XENE Hedge Fund Activity: Q1 2020 in Review

70 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Xenon Pharmaceuticals (XENE) for Q1 2020, worth a combined $314M — up 28% from $245M a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new XENE positions and 13 closed out — a net gain of 5 holders — while 22 added to existing stakes and 18 trimmed.

The largest buyer was Consonance Capital Management, opening a new position worth an estimated $28.2M. The largest seller was Acuta Capital Partners, cutting an estimated $4.12M.

  • 70 institutional investors held Xenon Pharmaceuticals (XENE) as of Q1 2020, up from 66 in Q4 2019.
  • Funds reported $314M of Xenon Pharmaceuticals stock for Q1 2020, up 28% quarter-over-quarter.
  • 18 funds opened new Xenon Pharmaceuticals positions in Q1 2020 and 13 closed out, a net change of +5 holders.
  • The largest Xenon Pharmaceuticals buyer in Q1 2020 was Consonance Capital Management, an estimated $28.2M added.
  • The largest Xenon Pharmaceuticals seller in Q1 2020 was Acuta Capital Partners, an estimated $4.12M sold.

Based on aggregated 13F filings for Q1 2020.